

Lise CUZIN - Publications 2014-2020

UMR 1027 : Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps.

Equipe EQUITY - Embodiment, social ineQualities, lifecoUrse epidemiology, cancer and chronic diseases, intervenTions, methodology

Articles dans des revues internationales ou nationales avec comité de lecture ou dans les bases de données internationales *Mise à jour juin 2020*

2020

1. Couffignal C, Kolta S, Flamant M, Cazanave C, Haymann JP, Mentré F, Duval X, Leport C, Raffi F, APROCO-COPILOTE ANRS CO8 Study Group (**Cuzin L** collaborator). Nevirapine Use Is Associated with Higher Bone Mineral Density in HIV-1 Positive Subjects on Long-Term Antiretroviral Therapy. *AIDS Res Hum Retroviruses*. 2020;36(5):399-405. doi:10.1089/AID.2019.0229.
2. Hentzien M, **Cuzin L**, Raffi F, Jacomet C, Reynes J, Rey D, Ravaux I, Cheret A, Viguier M, Bani-Sadr F, Dat'AIDS study group. Factors associated with psoriasis in a French Nationwide HIV cohort: the independent role of HLA-B*57:01. *AIDS*. 2020;34(7):1057-1063. doi:10.1097/QAD.0000000000002519.
3. Pircher M, Pitono E, Pierre-François S, Molcard S, Brunier-Agot L, Fagour L, Najioullah F, Cesaire R, Abel S, **Cuzin L**, Cabié A. The effects of chikungunya virus infection on people living with HIV during the 2014 Martinique outbreak. *PLoS One*. 2020;15(6):e0234267. Published 2020 Jun 5. doi:10.1371/journal.pone.0234267.
4. Poizot-Martin I, Obry-Roguet V, Duvivier C, Lions C, Huleux T, Jacomet C, Ferry T, Cheret A, Allavena C, Bani-Sadr F, Palich R, Cabié A, Fresard A, Pugliese P, Delobel P, Lamaury I, Hustache-Mathieu L, Bréigeon S, Makinson A, Rey D, Dat'AIDS study group (**Cuzin L** collaborator). Kaposi sarcoma among people living with HIV in the French DAT'AIDS cohort between 2010 and 2015. *J Eur Acad Dermatol Venereol*. 2020;34(5):1065-1073. doi:10.1111/jdv.16204.

2019

1. **Cuzin L**, Cotte L, Delpierre C, Allavena C, Valantin MA, Rey D, Delobel P, Pugliese P, Raffi F, Cabié A; Dat'AIDS Study group. Too fast to stay on track? Shorter time to first anti-retroviral regimen is not associated with better retention in care in the French Dat'AIDS cohort. *PLoS One*. 2019 Sep 6;14(9):e0222067.
2. **Cuzin L**, Pugliese P, Katlama C, Bani-Sadr F, Ferry T, Rey D, Lourenco J, Bregigeon S, Allavena C, Reynes J, Cabié A; Dat'AIDS Study Group. Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort. *J Antimicrob Chemother*. 2019 Mar 1;74(3):754-760. doi: 10.1093/jac/dky497.
3. Durier C, Corinne Desaint C, Lelièvre JD, Silbermann B, Pialoux G, **Cuzin L**, Bonnet B, Poizot-Martin I, Bouakane A, Paul C, Grabar S, Spire B, Meyer L, Launay O, ANRS/VRI COHVAC Study Group Long-term Safety and Vaccine-Induced Seropositivity in Healthy Volunteers From HIV Vaccine Trials. *AIDS*. 2019. 33 (13), 2061-2071.
4. Hentzien M, Dramé M, Delpierre C, Allavena C, Cabié A, **Cuzin L**, Rey D, Pugliese P, Hédelin G, Bani-Sadr F; Dat'AIDS Study Group. HIV-related excess mortality and age-related comorbidities in patients

UMR1027 - Equipe EQUITY - Lise Cuzin - Publications 2016-2020

with HIV aged ≥ 60 : a relative survival analysis in the French Dat'AIDS cohort. *BMJ Open*. 2019 Jan 25;9(1):e024841. doi: 10.1136/bmjopen-2018-024841.

5. Le Guillou A, Pugliese P, Raffi F, Cabie A, **Cuzin L**, Katlama C, Allavena C, Drame M, Cotte L, Bani-Sadr F; Dat'AIDS Study Group. Reaching the Second and Third Joint United Nations Programme on HIV/AIDS 90-90-90 Targets Is Accompanied by a Dramatic Reduction in Primary Human Immunodeficiency Virus (HIV) Infection and in Recent HIV Infections in a Large French Nationwide HIV Cohort. *Clin Infect Dis*. 2019 Aug 17. pii: ciz800.
6. Lions C, Cabras O, Cotte L, Huleux T, Gagneux-Brugnon A, Makinson A, Cabié A, Bonnet B, Duvivier C, Hocqueloux L, Cua E, Cheret A, Hustache-Mathieu L, Obry-Roguet V, Jacomet C, Poizot-Martin I; DAT'AIDS STUDY GROUP. (**Cuzin L** collaborator) Missed opportunities of HIV pre-exposure prophylaxis in France: a retrospective analysis in the French DAT'AIDS cohort. *BMC Infect Dis*. 2019 Mar 25;19(1):278. doi: 10.1186/s12879-019-3915-5.
7. Pugliese P, Joly V, Valantin MA, Cotte L, Huleux T, Allavena C, Reynes J, Poizot-Martin I, Bani-Sadr F, **Cuzin L**; Dat'AIDS group. Which antiretrovirals should be prescribed as first-line treatments? Changes over the past 10 years in France. *Med Mal Infect*. 2019 Jun;49(4):264-269. doi: 10.1016/j.medmal.2018.10.005.
8. Sagaon-Teyssier L, Vilotitch A, Mora M, Maradan G, Guagliardo V, Suzan-Monti M, Dray-Spira R, Spire B; VESPA2 study group. (**Cuzin L** collaborator) A generalized additive model to disentangle age and diagnosis-specific cohort effects in psychological and behavioral outcomes in people living with HIV: the French cross-sectional ANRS-VESPA2 survey. *BMC Public Health*. 2019 May 17;19(1):590. doi: 10.1186/s12889-019-6905-z.

2018

1. Abel S, **Cuzin L**, Da Cunha S, Bolivard JM, Fagour L, Miossec C, Pircher M, Thioune M, Césaire R, Cabié A. Reaching the WHO target of testing persons in jails in prisons will need diverse efforts and resources. *PLoS One*. 2018 Aug 30;13(8):e0202985. doi: 10.1371/journal.pone.0202985.
2. **Cuzin L**, Yazdanpanah Y, Huleux T, Cotte L, Pugliese P, Allavena C, Reynes J, Poizot-Martin I, Bani-Sadr F, Delpierre C; Dat'AIDS Study Group. No relationship between late HIV diagnosis and social deprivation in newly diagnosed patients in France. *HIV Med*. 2018 Mar;19(3):238-242. doi: 10.1111/hiv.12545.
3. Hentzien M, Cabie A, Pugliese P, Billaud É, Poizot-Martin I, Duvivier C, Valantin MA, Kaladjian A, Dramé M, Bani-Sadr F; Dat'AIDS Study Group. (**Cuzin L** collaborator) Factors associated with deaths from suicide in a French nationwide HIV-infected cohort. *HIV Med*. 2018 Jun 1. doi: 10.1111/hiv.12633. [Epub ahead of print]
4. Hentzien M, Delpierre C, Pugliese P, Allavena C, Jacomet C, Valantin MA, Cabié A, **Cuzin L**, Rey D, Bani-Sadr F, Dramé M; Dat'Aids Study Group. Derivation and internal validation of a mortality risk index for aged people living with HIV: The Dat'AIDS score. *PLoS One*. 2018 Apr 19;13(4):e0195725. doi: 10.1371/journal.pone.0195725.
5. Pressiat C, Hirt D, Treluyer JM, Zheng Y, Morlat P, Naqvi A, Tran L, Viard JP, Avettand-Fenoel V, Rouzioux C, Meyer L, Cheret A; OPTIPRIM Study Group (**Cuzin L** collaborator) Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial. *J Antimicrob Chemother*. 2018 Apr 1;73(4):1020-1024. doi: 10.1093/jac/dkx498.
6. Provoost A, Dramé M, Cotte L, **Cuzin L**, Garraffo R, Rey D, Raffi F, Poizot-Martin I, Pugliese P, Bani-Sadr F; Dat'AIDS study group. Risk of diabetes in HIV-infected patients is associated with cirrhosis but not

with chronic HCV coinfection in a French nationwide HIV cohort. *Aliment Pharmacol Ther.* 2018 Aug;48(3):281-289. doi: 10.1111/apt.14812.

7. Roul H, Mary-Krause M, Ghosn J, Delaugerre C, Pialoux G, **Cuzin L**, Launay O, Lacombe JM, Menard A, De Truchis P, Delfraissy JF, Weiss L, Costagliola D; FHDH-ANRS CO4. CD4+ cell count recovery after combined antiretroviral therapy in the modern combined antiretroviral therapy era. *AIDS.* 2018 Nov 13;32(17):2605-2614. doi: 10.1097/QAD.0000000000002010.
8. Suzan-Monti M, Celse M, Vilotitch A, Demoulin B, Dray-Spira R, Yéni P, Lert F, Spire B; ANRS VESPA2 study group (**Cuzin L** collaborator) Assesment of Awareness of, Concerns and Attitudes Towards HIV-Related Court-Case Sentences in France in a Representative Sample of People Living with HIV (ANRS VESPA2 Survey). *AIDS Behav.* 2018 Oct;22(10):3264-3272. doi: 10.1007/s10461-018-2077-6.

2017

1. **Cuzin L**, Katlama C, Cotte L, Pugliese P, Cheret A, Bernaud C, Rey D, Poizot-Martin I, Chirouze C, Bani-Sadr F, Cabié A; Dat'AIDS Study Group. Ageing with HIV: do comorbidities and polymedication drive treatment optimization? *HIV Med.* 2017 Jul;18(6):395-401. doi: 10.1111/hiv.12441.
2. **Cuzin L**, Pugliese P, Allavena C, Rey D, Chirouze C, Bani-Sadr F, Cabié A, Huleux T, Poizot-Martin I, Cotte L, Isnard Bagnis C, Flandre P; Dat'AIDS study group. Antiretroviral therapy as a risk factor for chronic kidney disease: Results from traditional regression modeling and causal approach in a large observational study. *PLoS One.* 2017 Dec 7;12(12):e0187517. doi: 10.1371/journal.pone.0187517.
3. Dutertre M, **Cuzin L**, Demonchy E, Pugliese P, Joly V, Valantin MA, Cotte L, Huleux T, Delobel P, Martin-Blondel G; dat'aids study group. Initiation of antiretroviral therapy containing integrase inhibitors increases the risk of IRIS requiring hospitalization. *J Acquir Immune Defic Syndr.* 2017 Sep 1;76(1):e23-e26. doi: 10.1097/QAI.0000000000001397.
4. Feuillet P, Lert F, Tron L, Aubriere C, Spire B, Dray-Spira R; Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS)-VIH: Enquête sur les personnes atteintes (Vespa2) Study Group (**Cuzin L** collaborator). Prevalence of and factors associated with depression among people living with HIV in France. *HIV Med.* 2017 Jul;18(6):383-394. doi: 10.1111/hiv.12438.
5. Gantner P, **Cuzin L**, Allavena C, Cabie A, Pugliese P, Valantin MA, Bani-Sadr F, Joly V, Ferry T, Poizot-Martin I, Garraffo R, Peytavin G, Fafi-Kremer S, Rey D; Dat'AIDS study group. Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study. *HIV Med.* 2017 Oct;18(9):704-708. doi: 10.1111/hiv.12506.
6. Lebrun D, Hentzien M, **Cuzin L**, Rey D, Joly V, Cotte L, Allavena C, Dellamonica P, Servettaz A, Bani-Sadr F; and the Dat'AIDS study group. Epidemiology of autoimmune and inflammatory diseases in a French nationwide HIV cohort. *AIDS.* 2017 Sep 24;31(15):2159-2166. doi: 10.1097/QAD.0000000000001603.
7. Metsu D, Seraissol P, Delobel P, Cinq-Frais C, **Cuzin L**, Izopet J, Chatelut E, Gandia P. Is the unbound concentration of atazanavir of interest in therapeutic drug monitoring? *Fundam Clin Pharmacol.* 2017 Apr;31(2):245-253. doi: 10.1111/fcp.12245.
8. Palich R, Martin-Blondel G, **Cuzin L**, Le Talec JY, Boyer P, Massip P, Delobel P. Experiences of HIV postexposure prophylaxis (PEP) among highly exposed men who have sex with men (MSM). *Sex Transm Infect.* 2017 Nov;93(7):493-498. doi: 10.1136/sextrans-2016-052901.
9. Pradat P, Pugliese P, Poizot-Martin I, Valantin MA, **Cuzin L**, Reynes J, Billaud E, Huleux T, Bani-Sadr F, Rey D, Frésard A, Jacomet C, Duvivier C, Cheret A, Hustache-Mathieu L, Hoen B, Cabié A, Cotte L; Dat'AIDS study Group. Direct-acting antiviral treatment against hepatitis C virus infection in HIV-

Infected patients - "En route for eradication"? J Infect. 2017 Sep;75(3):234-241. doi: 10.1016/j.jinf.2017.05.008.

10. Raffi F, Le Moing V, Assuied A, Habak S, Spire B, Cazanave C, Billaud E, Dellamonica P, Ferry T, Fagard C, Leport C; and the ANRS CO8 COPILOTE Study Group (**Cuzin L** collaborator). Failure to achieve immunological recovery in HIV-infected patients with clinical and virological success after 10 years of combined ART: role of treatment course. J Antimicrob Chemother. 2017 Jan;72(1):240-245.
11. Tron L, Lert F, Spire B, Dray-Spira R; Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS)-Vespa2 Study Group. (**Cuzin L** collaborator) Levels and determinants of breast and cervical cancer screening uptake in HIV-infected women compared with the general population in France. HIV Med. 2017 Mar;18(3):181-195. doi: 10.1111/hiv.12412.
12. Virlogeux V, Zoulim F, Pugliese P, Poizot-Martin I, Valantin MA, **Cuzin L**, Reynes J, Billaud E, Huleux T, Bani-Sadr F, Rey D, Frésard A, Jacomet C, Duvivier C, Cheret A, Hustache-Mathieu L, Hoen B, Cabié A, Cotte L; Dat'AIDS Study Group. Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination. BMC Med. 2017 Dec 18;15(1):217. doi: 10.1186/s12916-017-0979-1.

2016

1. Allavena C, Katlama C, Cotte L, Roger PM, Delobel P, Cheret A, Duvivier C, Poizot-Martin I, Hoen B, Cabié A, Cheret A, Lahoulou R, Raffi F, Pugliese P; Dat'AIDS Study group (**Cuzin L** collaborator) . Long-term efficacy and safety of etravirine-containing regimens in a real-life cohort of treatment-experienced HIV-1-infected patients. Infect Dis (Lond). 2016;48(5):392-8. doi: 10.3109/23744235.2015.1133927.
2. Cotte L, Pugliese P, Valantin MA, **Cuzin L**, Billaud E, Duvivier C, Naqvi A, Cheret A, Rey D, Pradat P, Poizot-Martin I; Dat'AIDS study Group. Hepatitis C treatment initiation in HIV-HCV coinfecting patients. BMC Infect Dis. 2016 Jul 22;16:345. doi: 10.1186/s12879-016-1681-1.
3. **Cuzin L**, Dellamonica P, Yazdanpanah Y, Bouchez S, Rey D, Hoen B, Cabié A; Dat'AIDS Study Group. Characteristics and consequences of medical care interruptions in HIV-infected patients in France. Epidemiol Infect. 2016 Aug;144(11):2363-70. doi: 10.1017/S0950268816000625.
4. Feuillet P, Lert F, Tron L, Aubriere C, Spire B, Dray-Spira R; Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS)-VIH: Enquête sur les personnes atteintes (Vespa2) Study Group (**Cuzin L** collaborator). Prevalence of and factors associated with depression among people living with HIV in France. HIV Med. 2016 Sep 14. doi: 10.1111/hiv.12438.
5. Flandre P, Pugliese P, Allavena C, Isnard Bagnis C, **Cuzin L**; Dat'AIDS study Group. Does first-line antiretroviral regimen impact risk for chronic kidney disease whatever the risk group? AIDS. 2016 Jun 1;30(9):1433-8. doi: 10.1097/QAD.0000000000001065.
6. Flandre P, Pugliese P, Allavena C, Katlama C, Cotte L, Cheret A, Cabié A, Rey D, Chirouze C, Bani-Sadr F, **Cuzin L**; Dat'AIDS Study group. Comparative risk of failure of ABC/3TC or TDF/FTC based first-line regimens in patients with a high viral load. HIV Med. 2016 May;17(5):380-4. doi: 10.1111/hiv.12306.
7. Garnier C, Martin-Blondel G, Debuissou C, Dubois D, Debard A, **Cuzin L**, Massip P, Delobel P, Marchou B. Intra-nodal injection of gentamicin for the treatment of suppurated cat scratch disease's lymphadenitis. Infection. 2016 Feb;44(1):23-7. doi: 10.1007/s15010-015-0797-3.
8. Hema MN, Ferry T, Dupon M, **Cuzin L**, Verdon R, Thiébaud R, Protopopescu C, Leport C, Raffi F, Le Moing V; ANRS CO 8 (APROCO/COPILOTE) study group. Low CD4/CD8 Ratio Is Associated with Non AIDS-Defining Cancers in Patients on Antiretroviral Therapy: ANRS CO8 (Aproco/Copilote) Prospective Cohort Study. PLoS One. 2016 Aug 22;11(8):e0161594. doi: 10.1371/journal.pone.0161594.
9. Hentzien M, Dramé M, Allavena C, Cabié A, **Cuzin L**, Rey D, Delpierre C, Pugliese P, Hédelin G, Bani-Sadr F. COL 3-02 - Les comorbidités liées à l'âge sont associées à l'excès de mortalité lié au VIH chez les

patients vivant avec le VIH de 60 ans et plus dans la cohorte Dat'AIDS. *Med Mal Infect.* 2016 Jun;46(4 Suppl 1):5. doi: 10.1016/S0399-077X(16)30267-0.

10. Hentzien M, Dramé M, Allavena C, Jacomet C, Valantin MA, Cabié A, **Cuzin L**, Rey D, Pugliese P, Bani-Sadr F; Dat'AIDS Study Group. Impact of Age-related Comorbidities on Five-year Overall Mortality among Elderly HIV-Infected Patients in the Late HAART Era--Role of Chronic Renal Disease. *J Nutr Health Aging.* 2016 Apr;20(4):408-14. doi: 10.1007/s12603-015-0608-7.
11. Lortholary O, Roussillon C, Boucherie C, Padoin C, Chaix ML, Breton G, Rami A, Veziris N, Patey O, Caumes E, May T, Molina JM, Robert J, Tod M, Fagard C, Chêne G; ANRS 129 BKVIR Trial Group (**Cuzin L** collaborator). Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial. *J Antimicrob Chemother.* 2016 Mar;71(3):783-93. doi: 10.1093/jac/dkv384.
12. Metsu D, Seraissol P, Delobel P, Cinq-Frais C, **Cuzin L**, Izopet J, Chatelut E, Gandia P. Is the unbound concentration of Atazanavir of interest in Therapeutic Drug Monitoring? *Fundam Clin Pharmacol.* 2016 Sep 24. doi: 10.1111/fcp.12245.
13. Palich R, Martin-Blondel G, **Cuzin L**, Le Talec JY, Boyer P, Massip P, Delobel P. VIH-09 - Prophylaxie post-exposition du VIH : expériences de consultation chez des homosexuels masculins devenus séropositifs. *Med Mal Infect.* 2016 Jun;46(4 Suppl 1):119-20. doi: 10.1016/S0399-077X(16)30554-6. French
14. Poizot-Martin I, Allavena C, Delpierre C, Duvivier C, Obry-Roguet V, Cano CE, Guillouet de Salvador F, Rey D, Dellamonica P, Cheret A, **Cuzin L**, Katlama C, Cabié A, Hoen B; Dat'AIDS Study Group. First-line cART regimen impacts the course of CD8+ T-cell counts in HIV-infected patients that achieve sustained undetectable viral load. *Medicine (Baltimore).* 2016 Oct;95(41):e5087.
15. Poizot-Martin I, Allavena C, Duvivier C, Cano CE, Guillouet de Salvador F, Rey D, Dellamonica P, **Cuzin L**, Cheret A, Hoen B; Dat'AIDS Study Group. CMV+ Serostatus Associates Negatively with CD4:CD8 Ratio Normalization in Controlled HIV-Infected Patients on cART. *PLoS One.* 2016 Nov 8;11(11):e0165774. doi: 10.1371/journal.pone.0165774..
16. Raffi F, Le Moing V, Assuied A, Habak S, Spire B, Cazanave C, Billaud E, Dellamonica P, Ferry T, Fagard C, Leport C; and the ANRS CO8 COPILOTE Study Group (**Cuzin L** collaborator). Failure to achieve immunological recovery in HIV-infected patients with clinical and virological success after 10 years of combined ART: role of treatment course. *J Antimicrob Chemother.* 2016 Sep 13. pii: dkw369
17. Raymond S, Nicot F, Carcenac R, Jeanne N, Cazabat M, Requena M, **Cuzin L**, Delobel P, Izopet J; ANRS 145 MARIMUNO Study Group. No selection of CXCR4-using variants in cell reservoirs of dual-mixed HIV-infected patients on suppressive maraviroc therapy. *AIDS.* 2016 Mar 27;30(6):965-8. doi: 10.1097/QAD.0000000000001013.
18. Suzan-Monti M, Lorente N, Demoulin B, Marcellin F, Préau M, Dray-Spira R, Lert F, Spire B; ANRS-VESPA2 Study Group (**Cuzin L** collaborator). Sexual risk behaviour among people living with HIV according to the biomedical risk of transmission: results from the ANRS-VESPA2 survey.. *J Int AIDS Soc.* 2016 Jan 8;19(1):20095. doi: 10.7448/IAS.19.1.20095.

2015

1. Abgrall S, Rachas A, Turret J, Isnard-Bagnis C, Billaud E, Tattevin P, Costagliola D, Guiguet M, Durieux P; French Hospital Database on HIV. (**Cuzin L** collaborator). A multifaceted intervention designed to improve medical management of moderate to advanced chronic kidney disease in HIV-infected patients: a cluster randomized trial. *Clin Infect Dis.* 2015 Aug 1;61(3):375-84. doi: 10.1093/cid/civ310.
2. Annequin M, Lert F, Spire B, Dray-Spira R; VESPA2 Study Group (**Cuzin L** collaborator). Has the employment status of people living with HIV changed since the early 2000s? *AIDS.* 2015 Jul 31;29(12):1537-47. doi: 10.1097/QAD.0000000000000722.
3. Bastard JP, Fellahi S, Couffignal C, Raffi F, Gras G, Hardel L, Sobel A, Leport C, Fardet L, Capeau J; ANRS CO8 APROCO-COPILOTE Cohort Study Group (**Cuzin L** collaborator). Increased systemic immune activation and inflammatory profile of long-term HIV-infected ART-controlled patients is related to

- personal factors, but not to markers of HIV infection severity *J Antimicrob Chemother.* 2015;70(6):1816-24. doi: 10.1093/jac/dkv036.
4. Chéret A, Bacchus-Souffan C, Avettand-Fenoël V, Mélard A, Nembot G, Blanc C, Samri A, Sáez-Cirión A, Hocqueloux L, Lascoux-Combe C, Allavena C, Goujard C, Valantin MA, Leplatois A, Meyer L, Rouzioux C, Autran B; OPTIPRIM ANRS-147 Study Group (**Cuzin L** collaborator).. Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission. *J Antimicrob Chemother.* 2015 Jul;70(7):2108-20. doi: 10.1093/jac/dkv084.
 5. Chéret A, Nembot G, Mélard A, Lascoux C, Slama L, Miallhes P, Yeni P, Abel S, Avettand-Fenoel V, Venet A, Chaix ML, Molina JM, Katlama C, Goujard C, Tamalet C, Raffi F, Lafeuillade A, Reynes J, Ravaux I, Hoën B, Delfraissy JF, Meyer L, Rouzioux C; OPTIPRIM ANRS Study Group (**Cuzin L** collaborator). Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial. *Lancet Infect Dis.* 2015 Apr;15(4):387-96. doi: 10.1016/S1473-3099(15)70021-6.
 6. **Cuzin L**, Pugliese P, Allavena C, Katlama C, Cotte L, Cheret A, Cabié A, Rey D, Chirouze C, Bani-Sadr F, Flandre P; Dat'AIDS Study group.. Comparative Effectiveness of First Antiretroviral Regimens in Clinical Practice Using a Causal Approach. *Medicine (Baltimore).* 2015 Sep;94(39):e1668. doi: 10.1097/MD.0000000000001668.
 7. **Cuzin L**, Pugliese P, Sauné K, Allavena C, Ghosn J, Cottalorda J, Rodallec A, Chaix ML, Fafi-Kremer S, Soulié C, Ouka M, Charpentier C, Bocket L, Mirand A, Guiguet M; Dat'AIDS study group.. Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy. *AIDS.* 2015 Aug 24;29(13):1665-71. doi: 10.1097/QAD.0000000000000723.
 8. Rey D, Piroth L, Wendling MJ, Miallhes P, Michel ML, Dufour C, Haour G, Sogni P, Rohel A, Ajana F, Billaud E, Molina JM, Launay O, Carrat F; ANRS HB04 B-BOOST study group. (**Cuzin L** collaborator). Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial. *Lancet Infect Dis.* 2015 Nov;15(11):1283-91. doi: 10.1016/S1473-3099(15)00220-0.
 9. Delaugerre C, Ghosn J, Lacombe JM, Pialoux G, **Cuzin L**, Launay O, Menard A, de Truchis P, Costagliola D; FHDH-ANRS CO4.. Significant reduction in HIV virologic failure during a 15-year period in a setting with free healthcare access. *Clin Infect Dis.* 2015 Feb 1;60(3):463-72. doi: 10.1093/cid/ciu834.
 10. HIV-CAUSAL Collaboration., Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Papanizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA. (**Cuzin L** collaborator). Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries. *Clin Infect Dis.* 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167.
 11. Lê MP, Soulié C, Assoumou L, Valantin MA, Duvivier C, Chas J, Ponscarne D, Marcelin AG, Calvez V, Katlama C, Peytavin G; ROCnRAL ANRS 157 Study Group. (**Cuzin L** collaborator). Plasma concentrations of maraviroc and raltegravir after dual therapy in patients with long-term suppressed viraemia: ROCnRAL ANRS 157 study. *J Antimicrob Chemother.* 2015 Aug;70(8):2418-20. doi: 10.1093/jac/dkv113. No abstract available.
 12. Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miró JM, Ferrer E, Justice A, Gandhi N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis F, Vandehende MA, Pérez-Hoyos S, Jarrín I, Jose S, Sabin C, Hernán MA; HIV-CAUSAL Collaboration (**Cuzin L** collaborator). Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. *Lancet HIV.* 2015 Aug;2(8):e335-43. doi: 10.1016/S2352-3018(15)00108-3.
 13. Maraux B, Hamelin C, Bajos N, Dray-Spira R, Spire B, Lert F; Vespa2 study group (**Cuzin L** collaborator). Women living with HIV still lack highly effective contraception: results from the ANRS VESPA2 study, France, 2011. *Contraception.* 2015 Aug;92(2):160-9. doi: 10.1016/j.contraception.2015.04.010.

14. Marcellin F, Demoulin B, Spire B, Suzan-Monti M, Roux P, Protopopescu C, Sagaon-Teyssier L, Duracinsky M, Dray-Spira R, Carrieri MP; ANRS-VESPA2 Study Group (**Cuzin L** collaborator). Spontaneous and post-treatment HCV clearance: relationships with health-related quality of life in HIV infection (ANRS-VESPA2 study). *Expert Rev Gastroenterol Hepatol*. 2015 May;9(5):701-13. doi: 10.1586/17474124.2015.1016914.
15. Marcellin F, Demoulin B, Suzan-Monti M, Maradan G, Carrieri MP, Dray-Spira R, Spire B; ANRS-VESPA2 Study Group (**Cuzin L** collaborator). Risk Factors for HCV Reinfection or Transmission in HIV-HCV Coinfected MSM (ANRS-VESPA2 French National Survey). *J Acquir Immune Defic Syndr*. 2015 Dec 15;70(5):e179-82. doi: 10.1097/QAI.0000000000000836.
16. Nicot F, Sauné K, Raymond S, Jeanne N, Carcenac R, Lefebvre C, **Cuzin L**, Marchou B, Delobel P, Izopet J. Minority resistant HIV-1 variants and the response to first-line NNRTI therapy. *J Clin Virol*. 2015 Jan;62:20-4. doi: 10.1016/j.jcv.2014.10.020.
17. Poizot-Martin I, Naqvi A, Obry-Roguet V, Valantin MA, Cuzin L, Billaud E, Cheret A, Rey D, Jacomet C, Duvivier C, Pugliese P, Pradat P, Cotte L; Hepadat'AIDS Study Group (**Cuzin L** collaborator). Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients. *PLoS One*. 2015 Oct 21;10(10):e0141164. doi: 10.1371/journal.pone.0141164.
18. Potard V, Reynes J, Ferry T, Aubin C, Finkielsztejn L, Yazdanpanah Y, Costagliola D; FHDH ANRS CO4 (**Cuzin L** collaborator). Durability and Effectiveness of Maraviroc-Containing Regimens in HIV-1-Infected Individuals with Virological Failure in Routine Clinical Practice. *PLoS One*. 2015 Dec 29;10(12):e0144746. doi: 10.1371/journal.pone.0144746.
19. Protopopescu C, Raffi F, Spire B, Hardel L, Michelet C, Cheneau C, Le Moing V, Leport C, Carrieri MP; ANRS CO8 APROCO-COPILOTE Study Group (**Cuzin L** collaborator). Twelve-year mortality in HIV-infected patients receiving antiretroviral therapy: the role of social vulnerability. The ANRS CO8 APROCO-COPILOTE cohort. *Antivir Ther*. 2015;20(7):763-72. doi: 10.3851/IMP2960.
20. Rosenthal E, Roussillon C, Salmon-Céron D, Georget A, Hénard S, Huleux T, Gueit I, Mortier E, Costagliola D, Morlat P, Chêne G, Cacoub P; Mortalité 2010 and GERMIVIC study groups (**Cuzin L** collaborator). Liver-related deaths in HIV-infected patients between 1995 and 2010 in France: the Mortavic 2010 study in collaboration with the Agence Nationale de Recherche sur le SIDA (ANRS) EN 20 Mortalité 2010 survey. *HIV Med*. 2015 Apr;16(4):230-9. doi: 10.1111/hiv.12204.
21. Soulié C, Assoumou L, Darty M, Rodriguez C, Donati F, Sayon S, Peytavin G, Valantin MA, Caby F, Schneider L, Canestri A, Costagliola D, Katlama C, Calvez V, Marcelin AG; ROCnRAL ANRS-157 Study Group (**Cuzin L** collaborator). Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial). *J Antimicrob Chemother*. 2015 Dec;70(12):3339-44. doi: 10.1093/jac/dkv280.

2014

1. Costagliola D, Lacombe JM, Ghosn J, Delaugerre C, Pialoux G, **Cuzin L**, Launay O, Ménard A, de Truchis P, Mary-Krause M, Weiss L, Delfraissy JF. CD4+ cell count recovery in naïve patients initiating cART, who achieved and maintained plasma HIV-RNA suppression. *J Int AIDS Soc*. 2014 Nov 2;17(4 Suppl 3):19481. doi: 10.7448/IAS.17.4.19481.
2. Douab T, Marcellin F, Vilotitch A, Protopopescu C, Préau M, Suzan-Monti M, Sagaon-Teyssier L, Lert F, Carrieri MP, Dray-Spira R, Spire B; ANRS-VESPA2 Study Group (**Cuzin L** collaborator). Health-related quality of life of people living with HIV followed up in hospitals in France: comparing trends and correlates between 2003 and 2011 (ANRS-VESPA and VESPA2 national surveys). *AIDS Care*. 2014;26 Suppl 1:S29-40. doi: 10.1080/09540121.2014.906553.
3. Geri G, Maynard M, Rosenthal E, Fontaine H, Lacombe K, Slama L, Goujard C, Loustaud-Ratti V, Bergmann JF, Morlat P, Vittecoq D, Alric L, Cacoub P; GERMIVIC Group. (**Cuzin L** collaborator). Care of hepatitis C virus infection in France: modifications in three consecutive surveys between 1995 and 2010. *Liver Int*. 2014 Oct;34(9):1349-57.

4. Katlama C, Assoumou L, Valantin MA, Soulié C, Duvivier C, Chablais L, Kolta S, Pialoux G, Mercié P, Simon A, Costagliola D, Peytavin G, Marcelin AG; ROCnRAL ANRS 157 Study Group. (**Cuzin L** collaborator). Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study. *J Antimicrob Chemother.* 2014 Jun;69(6):1648-52. doi: 10.1093/jac/dkt536.
5. Keita M, Perbost I, Pugliese-Wehrlen S, Abel S, Pugliese P, Enel P, **Cuzin L**, Lang T, Delpierre C; Dat'AIDS Group.. Incidences and risk factors of first-line HAART discontinuation: a limitation to the success of the "seek, test, treat, and retain" strategy? *AIDS Care.* 2014;26(8):1058-69. doi: 10.1080/09540121.2014.882490.
6. Pochard L, Hauviller L, **Cuzin L**, Eyvrard F, Sommet A, Montastruc JL, Bagheri H. [Use of Nadis(®) software to improve adverse drug reaction reporting of antiretroviral drugs: experience in south west of France (midi-pyrénées)]. *Thérapie.* 2014 Mar-Apr;69(2):149-55. doi: 10.2515/therapie/2013076. French.
7. Rosenthal E, Piroth L, Cua E, Joulié A, Ravaux I, Chauveau M, Lacombe K, Cotte L, Bonnard P, Weiss L, Longuet M, Pradier C, Cacoub P; GERMIVIC Study Group (**Cuzin L** collaborator). Preexposure prophylaxis (PrEP) of HIV infection in France: a nationwide cross-sectional study (PREVIC study). *AIDS Care.* 2014 Feb;26(2):176-85. doi: 10.1080/09540121.2013.803014.